Injectable nanogel can monitor blood-sugar levels and secrete insulin when needed.
A story in the March 19 issue of MIT Tech Talk incorrectly identified Acusphere. Acusphere is an MIT startup that began Phase III clinical trials in February for an ultrasound contrast agent that detects coronary artery disease in patients with ischemic heart disease. The agent was designed by MIT Professor Robert Langer.
A version of this article appeared in MIT Tech Talk on April 2, 2003.